Amicus (FOLD) Stock Forecast & Price Target

Compare

1,106 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FOLD Analyst Ratings

Moderate Buy

4 Buy

4 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Amicus

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FOLD Stock 12 Month Forecast

Average Price Target

$14.57

▲(2.75% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Amicus in the last 3 months. The average price target is $14.57 with a high forecast of $19.00 and a low forecast of $11.00. The average price target represents a 2.75% change from the last price of $14.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","8":"$8","12":"$12","16":"$16","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8,12,16,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,10.507692307692308,11.215384615384616,11.923076923076923,12.630769230769232,13.338461538461539,14.046153846153846,14.753846153846155,15.461538461538462,16.16923076923077,16.876923076923077,17.584615384615383,18.29230769230769,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,10.166923076923078,10.533846153846154,10.900769230769232,11.267692307692307,11.634615384615385,12.001538461538463,12.368461538461538,12.735384615384616,13.102307692307694,13.46923076923077,13.836153846153847,14.203076923076924,{"y":14.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,9.892307692307693,9.984615384615385,10.076923076923077,10.16923076923077,10.261538461538462,10.353846153846154,10.446153846153846,10.538461538461538,10.63076923076923,10.723076923076924,10.815384615384616,10.907692307692308,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$14.57

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ritu Baral

TD Cowen

$20→$14.5

Hold

2.26%

Upside

Downgraded

12/19/25

Amicus (FOLD) was downgraded to a Hold Rating at TD Cowen

Kristen Kluska

Cantor Fitzgerald

$21→$14.5

Hold

2.26%

Upside

Downgraded

12/19/25

Amicus downgraded to Neutral from Overweight at Cantor FitzgeraldAmicus downgraded to Neutral from Overweight at Cantor Fitzgerald

Gil Blum

Needham

Hold

―

Downgraded

12/19/25

Amicus (FOLD) was downgraded to a Hold Rating at Needham

Samantha Semenkow

Citi

$17

Buy

19.89%

Upside

Initiated

12/17/25

Amicus initiated with a Buy at CitiAmicus initiated with a Buy at Citi

Maxwell Skor

Morgan Stanley

$12

Buy

-15.37%

Downside

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioCryst (NASDAQ: BCRX), Arcus Biosciences (NYSE: RCUS) and Amicus (NASDAQ: FOLD)

Anupam Rama

J.P. Morgan

$18→$19

Buy

33.99%

Upside

Reiterated

11/06/25

Amicus price target raised to $19 from $18 at JPMorganAmicus price target raised to $19 from $18 at JPMorgan

Salveen Richter

Goldman Sachs

$9→$11

Hold

-22.43%

Downside

Reiterated

11/05/25

Amicus price target raised to $11 from $9 at Goldman SachsAmicus price target raised to $11 from $9 at Goldman Sachs

Tazeen Ahmad

Bank of America Securities

$14

Buy

-1.27%

Downside

Reiterated

11/05/25

Bank of America Securities Sticks to Its Buy Rating for Amicus (FOLD)

Dennis Ding

Jefferies

$16

Buy

12.83%

Upside

Reiterated

09/16/25

Jefferies says Galafold summary judgment as expected, may facilitate settlementJefferies says Galafold summary judgment as expected, may facilitate settlement

Joseph Schwartz

Leerink Partners

$17

Buy

19.89%

Upside

Reiterated

08/01/25

Amicus's Strong Performance and Growth Potential Drive Buy Rating

Tiago Fauth

Wells Fargo

$17→$13

Buy

-8.32%

Downside

Reiterated

05/02/25

Amicus Therapeutics (FOLD) PT Lowered to $13 at Wells FargoWells Fargo lowered its price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $17.00) while maintaining a Overweight rating.

Eliana Merle

UBS

$21→$22

Buy

55.15%

Upside

Reiterated

05/02/25

Amicus price target raised to $22 from $21 at UBSAmicus price target raised to $22 from $21 at UBS

Debjit Chattopadhyay

Guggenheim

$15

Buy

5.78%

Upside

Reiterated

02/20/25

We maintain our BUY rating and PT of $15/share based on our 8-year DCF-based, sum-of- the-parts analysis driven by: beta of 1.1; terminal growth rate of 1%; risk premium of 4.2%; estimated WACC of 7.6% (prior 9%, updated based on revised cost of equity); and tax rate of 15% beginning in FY 2025.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ritu Baral

TD Cowen

$20→$14.5

Hold

2.26%

Upside

Downgraded

12/19/25

Amicus (FOLD) was downgraded to a Hold Rating at TD Cowen

Kristen Kluska

Cantor Fitzgerald

$21→$14.5

Hold

2.26%

Upside

Downgraded

12/19/25

Amicus downgraded to Neutral from Overweight at Cantor FitzgeraldAmicus downgraded to Neutral from Overweight at Cantor Fitzgerald

Gil Blum

Needham

Hold

―

Downgraded

12/19/25

Amicus (FOLD) was downgraded to a Hold Rating at Needham

Samantha Semenkow

Citi

$17

Buy

19.89%

Upside

Initiated

12/17/25

Amicus initiated with a Buy at CitiAmicus initiated with a Buy at Citi

Maxwell Skor

Morgan Stanley

$12

Buy

-15.37%

Downside

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioCryst (NASDAQ: BCRX), Arcus Biosciences (NYSE: RCUS) and Amicus (NASDAQ: FOLD)

Anupam Rama

J.P. Morgan

$18→$19

Buy

33.99%

Upside

Reiterated

11/06/25

Amicus price target raised to $19 from $18 at JPMorganAmicus price target raised to $19 from $18 at JPMorgan

Salveen Richter

Goldman Sachs

$9→$11

Hold

-22.43%

Downside

Reiterated

11/05/25

Amicus price target raised to $11 from $9 at Goldman SachsAmicus price target raised to $11 from $9 at Goldman Sachs

Tazeen Ahmad

Bank of America Securities

$14

Buy

-1.27%

Downside

Reiterated

11/05/25

Bank of America Securities Sticks to Its Buy Rating for Amicus (FOLD)

Dennis Ding

Jefferies

$16

Buy

12.83%

Upside

Reiterated

09/16/25

Jefferies says Galafold summary judgment as expected, may facilitate settlementJefferies says Galafold summary judgment as expected, may facilitate settlement

Joseph Schwartz

Leerink Partners

$17

Buy

19.89%

Upside

Reiterated

08/01/25

Amicus's Strong Performance and Growth Potential Drive Buy Rating

Tiago Fauth

Wells Fargo

$17→$13

Buy

-8.32%

Downside

Reiterated

05/02/25

Amicus Therapeutics (FOLD) PT Lowered to $13 at Wells FargoWells Fargo lowered its price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $17.00) while maintaining a Overweight rating.

Eliana Merle

UBS

$21→$22

Buy

55.15%

Upside

Reiterated

05/02/25

Amicus price target raised to $22 from $21 at UBSAmicus price target raised to $22 from $21 at UBS

Debjit Chattopadhyay

Guggenheim

$15

Buy

5.78%

Upside

Reiterated

02/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amicus

1 Month

xxx

Success Rate

9/14 ratings generated profit

Average Return

+2.46%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +2.46% per trade.

3 Months

xxx

Success Rate

10/15 ratings generated profit

Average Return

+8.01%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.01% per trade.

1 Year

Debjit ChattopadhyayGuggenheim

Success Rate

8/14 ratings generated profit

Average Return

+22.65%

reiterated a buy rating 10 months ago

Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +22.65% per trade.

2 Years

xxx

Success Rate

8/16 ratings generated profit

Average Return

+9.47%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +9.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FOLD Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FOLD has received 10 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. FOLD average Analyst price target in the past 3 months is 14.57.

Each month's total comprises the sum of three months' worth of ratings.

FOLD Financial Forecast

FOLD Earnings Forecast

Next quarter’s earnings estimate for FOLD is $0.07 with a range of $0.03 to $0.09. The previous quarter’s EPS was $0.06. FOLD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year FOLD has Performed in-line its overall industry.

FOLD Sales Forecast

Next quarter’s sales forecast for FOLD is $179.70M with a range of $174.31M to $184.74M. The previous quarter’s sales results were $169.06M. FOLD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year FOLD has Performed in-line its overall industry.

FOLD Stock Forecast FAQ

What is FOLD’s average 12-month price target, according to analysts?

Based on analyst ratings, Amicus Therapeutics’s 12-month average price target is 14.57.

What is FOLD’s upside potential, based on the analysts’ average price target?

Amicus Therapeutics has 2.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FOLD a Buy, Sell or Hold?

Amicus Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 4 hold ratings and 0 sell ratings.

What is Amicus Therapeutics’s price target?

The average price target for Amicus Therapeutics is 14.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $11.00. The average price target represents 2.75% Increase from the current price of $14.18.

What do analysts say about Amicus Therapeutics?

Amicus Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of FOLD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amicus (FOLD) Stock Forecast & Price Target

FOLD Analyst Ratings

FOLD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amicus

FOLD Analyst Recommendation Trends

FOLD Financial Forecast

FOLD Earnings Forecast

FOLD Sales Forecast

FOLD Stock Forecast FAQ

Detailed List of Analyst Forecasts